AI in Oncology Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook (2026-2035)

The global AI in oncology market was valued at USD 4.65 Billion in 2025. It is poised to grow at a CAGR of 28.92% during the forecast period of 2026-2035, and reach USD 58.97 Billion by 2035. The market growth is driven by rising global cancer burden, increasing adoption of AI-driven diagnostics, and growing demand for precision oncology, enabling early detection, improved treatment planning, and enhanced clinical outcomes.

Q1 2026 Market Updates

Geopolitical Impact of Iran, US, and Israel War on the AI in Oncology Market

United States: The AI in Oncology Market, a key segment of the global economy, is experiencing a complex operating environment in Q1 2026 as a direct consequence of the US-Israel-Iran war. Petrochemical-derived pharmaceutical packaging materials including blister packs, polymer bottles, and specialty film coatings are facing 15-20% cost inflation from the Gulf supply disruption. API production costs are rising as petrochemical reagent prices increase 15-20%. Air freight costs have spiked dramatically, with temperature-sensitive pharmaceutical distribution facing elevated costs and extended lead times as Gulf carrier networks remain suspended. Consumer spending caution is growing as gasoline above USD 4 per gallon and 4.2% projected inflation compress household discretionary budgets. Clinical trial operations in Middle Eastern investigator sites have been disrupted, and medical supply chains face elevated logistics costs.

Iran: Iran's healthcare system has been severely damaged by the conflict, with the WHO identifying at least 13 health facilities as conflict-damaged. The domestic pharmaceutical and medical device sector, already severely constrained by sanctions limiting access to Western medical technology and APIs, has been further disrupted by power outages, workforce displacement, and the collapse of medical supply chain logistics. Iranian patients requiring treatment for ai in oncology conditions face an acute access crisis, as hospital operations are redirected toward treating conflict casualties and basic medical supplies are running low.

Israel: Israel's pharmaceutical and medical device sector is operating under emergency conditions. Israeli hospitals have moved some operations underground, medical resources are being prioritised for conflict casualties, and elective and non-emergency healthcare consumption has declined. However, Israel's biopharmaceutical research base continues to operate, with several Israeli companies involved in novel treatment development for ai in oncology indications. Post-conflict, Israel's healthcare system is expected to invest significantly in medical technology and pharmaceutical infrastructure restoration and capacity expansion.

Key Takeaways

Government

• Relevant health authorities should activate emergency pharmaceutical supply chain resilience protocols, ensuring that API and packaging material sourcing for essential ai in oncology treatments is not concentrated in Gulf-adjacent supply chains exposed to maritime disruption.
• Regulatory agencies should fast-track review of treatment availability and consider emergency compassionate use extensions for patients in conflict-affected regions who face interruption to their standard of care.
• Governments should monitor petrochemical-derived pharmaceutical packaging cost inflation, ensuring that price increases remain within access thresholds for patients requiring ongoing ai in oncology treatment.

Market

• Petrochemical-derived pharmaceutical packaging and API precursor costs are rising 15-20%, creating margin compression for ai in oncology manufacturers in the near term, with limited ability to pass costs through in price-regulated markets.
• The conflict's disruption to clinical trial infrastructure in Middle Eastern sites may modestly delay regulatory submissions and new treatment launches that had enrolled patients from the region, though the structural market growth trajectory remains intact.
• Healthcare system demand for ai in oncology treatment is fundamentally driven by disease burden and demographics rather than geopolitical events, providing strong structural insulation for the market's long-term growth trajectory.

Procurement

• Pharmaceutical procurement teams should build 90-day safety stock for essential ai in oncology treatment drugs and biological agents, hedging against further pharmaceutical logistics cost increases and potential supply disruptions.
• API and excipient buyers should review single-source supplier risks for Gulf-adjacent petrochemical-derived pharmaceutical inputs, establishing secondary supply arrangements with non-Gulf origin manufacturers in India, China, and Europe.
• Hospital pharmacy procurement managers should review cold-chain logistics contracts for temperature-sensitive ai in oncology therapeutics, ensuring that alternative air routing through non-conflict-zone hubs is available if Gulf carrier services remain suspended.

Key Market Trends and Insights

• North America dominated the market in the historical period, accounting for the largest revenue share of over 45%.
• Based on component, the hardware segment led the market, capturing the highest revenue share of around 40% in the historical period.
• Based on cancer type, the breast cancer segment held the leading position, contributing approximately 21% of the total revenue share in the historical period.

Market Size and Forecast

• Market Size (2025): USD 4.65 Billion
• Projected Market Size (2035): USD 58.97 Billion
• CAGR (2026-2035): 28.92%

AI in Oncology Market Overview

AI is transforming oncology by improving early cancer detection, enhancing diagnostic accuracy, and enabling personalized treatment planning. It analyzes medical imaging, genomic data, and clinical records to identify patterns that support precise decision-making. AI also accelerates drug discovery, optimizes clinical trials, and predicts treatment responses, reducing time and costs. Additionally, it enables real-time patient monitoring and risk assessment, improving outcomes and survival rates. By streamlining workflows and reducing human error, AI enhances efficiency across oncology care, supporting better patient management and advancing precision oncology globally. The market reached a value of approximately USD 4.65 Billion in 2025.

AI in Oncology Market Growth Drivers

AI-Powered Oncology Platform Launches Driving the Market Value

Rising demand for faster drug discovery and precision oncology solutions is a key market driver. For instance, in September 2025, Eli Lilly launched an AI-powered platform designed to accelerate drug discovery, including oncology-focused therapeutic development. This innovation highlights how AI is being integrated into core R&D processes to improve biomarker identification and reduce development timelines. Such product launches are expected to significantly drive market growth by enhancing research efficiency, lowering costs, and enabling faster delivery of novel cancer treatments.

AI in Oncology Market Trends

Key trends shaping the market include rising AI adoption, regulatory support, increasing R&D investments, growing precision oncology demand, and advancements in AI-assisted diagnosis and data-driven clinical decision-making.

Regulatory Support for AI Adoption Boosting the Market Demand

Growing emphasis on ethical research practices and faster drug development is shaping market trends. For instance, in September 2025, the FDA supported increased adoption of AI in drug discovery, particularly in oncology, to reduce reliance on animal testing and accelerate therapeutic development timelines. This trend reflects a broader regulatory shift toward integrating AI into core research processes. Such support is expected to advance market development by encouraging innovation, improving efficiency, and promoting wider adoption of AI-driven approaches in cancer treatment discovery and development, including advancements in radiology AI and oncology imaging.

AI in Oncology Market Segmentation

Market Breakup by Component

• Hardware
• Software
• Services

Market Breakup by Cancer Type

• Breast Cancer
• Colorectal Cancer
• Lung Cancer
• Brain Tumor
• Prostate Cancer
• Others

Market Breakup by Application

• Cancer Detection
• Drug Discovery
• Drug Development
• Others

Market Breakup by Treatment

• Chemotherapy
• Immunotherapy
• Radiotherapy
• Others

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

AI in Oncology Market Share

Hardware Leads the Market Segment by Component

The market is witnessing strong growth across multiple components, with hardware playing a crucial enabling role. Based on component, the hardware segment led the market with the largest revenue share of over 40% in the historical period, driven by increasing demand for high-performance computing, GPUs, and specialized processors required for complex oncology data analysis. These technologies support oncology imaging, diagnostics, and real-time analytics, enhancing clinical decision-making. Additionally, advancements in computational infrastructure and growing adoption of AI-powered diagnostic tools continue to reinforce the dominance of hardware within the market.

Global AI in Oncology Market Analysis by Region

The market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa, with varying levels of adoption and growth. North America dominated the market with the largest revenue share of approximately 45% in the historical period, supported by advanced healthcare infrastructure, strong research funding, and early adoption of AI technologies, particularly in cancer screening and tumor detection. The presence of leading technology and pharmaceutical companies further strengthens regional leadership. Meanwhile, Asia Pacific is expected to experience rapid growth due to increasing cancer burden and expanding healthcare investments, along with rising adoption of radiology AI and digital pathology solutions.

Leading Players in the AI in Oncology Market

The key features of the market report comprise patent analysis, funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:

GE HealthCare

Headquartered in Chicago, Illinois, and established in 1994 (as a GE division, now independent), GE HealthCare is a leading medical technology company. Its portfolio includes imaging systems, clinical decision support tools, and cloud-based applications like CareIntellect for Oncology, which integrates multimodal patient data to improve treatment insights. In October 2024, GE HealthCare launched this AI-powered platform to streamline cancer care workflows and enhance clinical decision-making, supporting precision oncology initiatives.

NVIDIA Corporation

Founded in 1993 and headquartered in Santa Clara, California, NVIDIA Corporation is a global leader in accelerated computing and AI technologies. In the oncology market, NVIDIA provides GPU-powered platforms, including Clara and BioNeMo, supporting medical imaging, genomics, and drug discovery. Its solutions enable high-speed processing of complex oncology datasets and AI model development. Recent collaborations with healthcare and life sciences organizations highlight NVIDIA’s role in advancing AI-driven cancer research, including generative AI and multimodal models for precision oncology applications.

ConcertAI LLC

ConcertAI LLC, headquartered in Cambridge, Massachusetts, and founded in 2018, specializes in AI-driven oncology data and analytics. The company offers SaaS platforms such as CARAai™, combining real-world data, predictive analytics, and generative AI to support clinical development and treatment optimization. Its portfolio serves life sciences companies and healthcare providers globally. In January 2025, ConcertAI expanded its AI capabilities and collaborated with NVIDIA to enhance oncology-focused AI models and data curation, strengthening its position in precision oncology and clinical research innovation.

PathAI

PathAI, founded in 2016 and headquartered in Boston, Massachusetts, is a leading AI-powered pathology company focused on improving cancer diagnosis and drug development. Its portfolio includes machine learning-based diagnostic tools, digital pathology platforms, and biomarker discovery solutions used in oncology research and clinical trials. PathAI collaborates with pharmaceutical companies to enhance trial accuracy and patient stratification. The company continues to expand its AI capabilities to support precision oncology, enabling more accurate disease detection and improved therapeutic decision-making in cancer care.

Other key players in the market are Azra AI, IBM Corporation, Siemens Healthineers AG, Intel Corporation, Digital Diagnostics Inc., Medtronic plc., and Median Technologies.

Key Questions Answered in the AI in Oncology Market

• What was the AI in oncology market value in 2025?
• What is the AI in oncology market forecast outlook for 2026-2035?
• What major factors aid the demand for AI in oncology market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market’s major drivers, opportunities, and restraints?
• What are the major AI in oncology market trends?
• Which component is expected to dominate the market segment?
• Which cancer type is anticipated to drive the market segment?
• Which application is likely to dominate the market segment?
• Which treatment is likely to dominate the market segment?
• Who are the key players in the AI in oncology market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?